Pliant Therapeutics, Inc
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. Its pipeline centers on oral and antibody drug candidates that modulate integrin biology and TGF-β signaling for oncology, fibrosis, and other disease areas.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaIncludes PLN-101095 and related development work in solid tumors resistant to immune checkpoint inhibitors.
Includes bexotegrast and other integrin-targeted programs aimed at fibrotic and inflammatory indications.
Includes PLN-101325, a monoclonal antibody program for muscular dystrophies.
Includes the integrin-binding library, screening assays, and translational tools used to generate new candidates.
Asiakkaat
Pliant does not sell commercial products today; its primary counterparties are clinical trial sites, contract research organizations, contract manufacturers, and development collaborators. If approved, its future customers would include physicians, hospitals, specialty pharmacies, and third-party payors in oncology and other specialty-care settings.
CROs, clinical sites, and CMOs that execute trials, supply materials, and support regulatory development.
Biopharma partners that may help develop or commercialize programs in larger indications or outside North America.
Oncologists, hospitals, and third-party payors that would determine uptake of PLN-101095 if approved.
Specialists treating fibrotic or neuromuscular diseases that could adopt approved pipeline therapies.
Strategia
Pliant’s strategy is to advance integrin-based drug candidates through early clinical development and use its platform to generate additional programs. It also seeks selective partnerships for larger indications and non-North American geographies, while expanding into adjacent areas such as immunology, inflammation, and oncology.
This is the lead clinical asset and the main path to value creation.
The proprietary library and assays can generate multiple follow-on candidates.
Partnerships can add commercial and development capabilities where internal reach is limited.
Maantiede
Pliant is headquartered in the United States and conducts its research and development from U.S.-based operations. Its disclosures also indicate interest in partnering for geographies outside North America, while clinical development may extend to sites in other countries such as Australia.
Riskit
Pliant’s business depends on successful clinical development, regulatory approval, and eventual market acceptance of highly uncertain product candidates. It also faces financing, CRO/supply-chain, competition, and healthcare-regulatory risks that are typical for clinical-stage biopharma and can materially delay or prevent commercialization.
- Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
Lead programs are still in early trials and may not show sufficient efficacy or safety.
Kohdistuu - Regulatory and reimbursement riskVaikutus: KorkeaTodennäköisyys: Korkea
Approval, pricing, coverage, and anti-kickback rules can block or limit commercialization.
Kohdistuu: U.S. and ex-U.S. healthcare markets
- Competitive pressureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Larger biopharma and biotech peers may reach approval faster or with better data.
Kohdistuu - Third-party execution and supply riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Trials depend on CROs, CMOs, and external suppliers for study execution and materials.
Kohdistuu: Clinical operations and combination therapy supply
- Capital and dilution riskVaikutus: Korkea
The company has no commercial product revenue and must fund long-duration R&D.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätClinical and preclinical costs are recognized as incurred, so trial cadence drives reported expense.
Vaikutus: Quarterly operating loss volatility
Employee and director equity awards are a recurring non-cash expense for a development-stage company.
Vaikutus: Reported operating expenses and loss per share
The company has a non-cancelable office and laboratory lease through 2031.
Vaikutus: Lease liabilities and fixed cash commitments
Accruals for CROs, CMOs, and trial services depend on estimates of work performed.
Vaikutus: Accrued liabilities and period expense recognition
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Cogent Biosciences, Inc.
COGT · Pharmaceutical Preparations
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
Tempest Therapeutics, Inc.
TPST · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Liminatus Pharma, Inc.
LIMNW · Biological Products, (No Diagnostic Substances)
Propanc Biopharma, Inc.
PPCB · Pharmaceutical Preparations
Päivitetty: 24.9.2026